Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

World Health Organization (WHO)-recommended preclinical in vivo and in vitro studies were carried out to compare the efficacy of Brazilian, Peruvian and Colombian antivenoms in neutralizing the venom toxins responsible for the lethal, haemorrhagic, necrotizing, coagulant and defibrinogenating effects of five medically-important Peruvian snake venoms. Overall, the Brazilian antivenom was found to be the most effective followed by the Peruvian and Colombian antivenoms. However, it was concluded that all three antivenoms would be acceptable for use in a randomised clinical trial in envenomed humans in Peru.

Original publication

DOI

10.1016/j.toxicon.2004.03.020

Type

Journal article

Journal

Toxicon

Publication Date

07/2004

Volume

44

Pages

103 - 106

Keywords

Animals, Antivenins, Blood Coagulation, Crotalid Venoms, Drug Evaluation, Preclinical, Fibrinogen, Hemorrhage, Lethal Dose 50, Mice, Necrosis, Neutralization Tests, Plasma, Snake Bites, South America, Species Specificity, Viperidae